PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32027909-2	2020	Somatostatin (SST) is one neuropeptide known to significantly contribute to emotionality and stress behaviors.	Somatostatin	0-12	somatostatin	Homo sapiens	14-17
31984458-4	2020	Somatostatin analogues are alternative options for GH, ACTH and TSH-secreting tumors.	Somatostatin	0-12	proopiomelanocortin	Homo sapiens	55-59
32015474-11	2020	Secretin stimulated somatostatin secretion (fold change: 1.59, P < 0.05) from the perfused rat pancreas but affected neither insulin (P = 0.2) nor glucagon (P = 0.97) secretion.	Somatostatin	20-32	secretin	Rattus norvegicus	0-8
31931619-5	2020	In cultures of dispersed islets NOX5 protein was observed in somatostatin-positive (delta) cells in basal (2.8mM glucose) conditions.	Somatostatin	61-73	NADPH oxidase 5	Homo sapiens	32-36
32029751-7	2020	SST downregulation in specific cortical and striatal subregions, with additional deficits in somatostatin-related signalling through SSTR2, may contribute to some of the adult behavioural changes resulting from MIA and its timing.	Somatostatin	93-105	somatostatin receptor 2	Rattus norvegicus	133-138
31743111-4	2020	The results demonstrate that the antidepressant actions of ketamine were blocked by GluN2B-NMDAR knockdown on GABA (Gad1) interneurons, as well as subtypes expressing somatostatin (Sst), or parvalbumin (Pvalb), but not glutamate principle neurons in the mPFC.	Somatostatin	181-184	somatostatin	Homo sapiens	167-179
31743111-5	2020	Further analysis of GABA subtypes showed that cell specific knockdown or deletion of GluN2B in Sst interneurons blocked or occluded the antidepressant actions of ketamine and revealed sex-specific differences that are associated with excitatory postsynaptic currents on mPFC principle neurons.	Somatostatin	95-98	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	85-91
32073399-6	2020	Furthermore, Stxbp1 haploinsufficiency reduced cortical inhibitory neurotransmission via distinct mechanisms from parvalbumin-expressing and somatostatin-expressing interneurons.	Somatostatin	141-153	syntaxin binding protein 1	Mus musculus	13-19
31996750-8	2020	Putative parvalbumin-expressing CA1 interneurons and somatostatin-expressing CA3 interneurons represented speed more retrospectively than parvalbumin-expressing CA3 interneurons.	Somatostatin	53-65	carbonic anhydrase 3	Rattus norvegicus	77-80
31997090-13	2020	Further, the production process and quality control developed for [18F]AlF-NOTA-octreotide is easily implementable in a clinical setting and the tracer is a potential clinical alternative for somatostatin directed 68Ga labeled peptides obviating the need for a 68Ge/68Ga-generator.	Somatostatin	192-204	hepatocyte specific developmental regulation 1	Mus musculus	71-74
32062323-10	2020	CONCLUSIONS: Expression of SSTRs and activation of mTOR pathway in paediatric glioneuronal tumour suggest that somatostatin analogues and mTOR inhibitors may have potential therapeutic implications in a subset of inoperable childhood glioneuronal tumours causing medically refractory epilepsy and/or tumour growth.	Somatostatin	111-123	mechanistic target of rapamycin kinase	Homo sapiens	51-55
31952333-1	2020	Somatostatin (SOM) is the most common agent in the gastrointestinal (GI) tract that is involved in the regulation of several gastric functions, as well as in gastric disorders.	Somatostatin	14-17	somatostatin	Sus scrofa	0-12
31875303-8	2020	Tumours resistant to first-generation somatostatin analogues had lower CD8+ lymphocytes (median 1/HPF, IQR: 2.4) compared with responders (median 2.4/HPF, IQR: 2.9; P = 0.005).	Somatostatin	38-50	CD8a molecule	Homo sapiens	71-74
31875303-11	2020	CONCLUSIONS: Our study suggests that a lower number of CD8+ lymphocytes is associated with cavernous sinus invasion and resistance to treatment with first-generation somatostatin analogues in acromegaly patients.	Somatostatin	166-178	CD8a molecule	Homo sapiens	55-58
31733832-0	2020	Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway.	Somatostatin	0-12	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	32-36
31733832-0	2020	Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway.	Somatostatin	0-12	somatostatin receptor 5	Homo sapiens	56-61
31733832-0	2020	Somatostatin stimulates colonic MUC2 expression through SSTR5-Notch-Hes1 signaling pathway.	Somatostatin	0-12	hes family bHLH transcription factor 1	Homo sapiens	68-72
31733832-3	2020	Somatostatin (SST) has been found to play a role in colon protection through various manners.	Somatostatin	0-12	somatostatin	Homo sapiens	14-17
31733832-6	2020	In vivo study, exogenous somatostatin (octreotide) administration effectively stimulated mice colonic MUC2 expression and mucus secretion.	Somatostatin	25-37	mucin 2	Mus musculus	102-106
31911591-4	2020	In particular, somatostatin-expressing (SST) interneurons selectively inhibit dendrites and regulate synaptic inputs, yet their response to systemic NMDAR antagonism is unknown.	Somatostatin	15-27	somatostatin	Mus musculus	40-43
31873798-4	2020	SST is not only a marker of a specific interneuron subtype, but also an important neuropeptide that participates in numerous biochemical and signalling pathways in the brain via somatostatin receptors (SSTR1-5).	Somatostatin	178-190	somatostatin	Mus musculus	0-3
31873798-4	2020	SST is not only a marker of a specific interneuron subtype, but also an important neuropeptide that participates in numerous biochemical and signalling pathways in the brain via somatostatin receptors (SSTR1-5).	Somatostatin	178-190	somatostatin receptor 1	Mus musculus	202-207
31676823-1	2019	Medial ganglionic eminence (MGE)-derived somatostatin (SST)+ and parvalbumin (PV)+ cortical interneurons (CINs), have characteristic molecular, anatomical and physiological properties.	Somatostatin	55-58	somatostatin	Homo sapiens	41-53
31807924-5	2020	Since growth hormone secretion is regulated by the antagonistic actions of both GHRH and somatostatin, in the present paper we have examined the possibility that SP may also affect growth via the somatostatinergic system.	Somatostatin	89-101	growth hormone 1	Homo sapiens	6-20
31807924-7	2020	In the present study, we have revealed a dense network of substance P-IR axonal varicosities contacting the majority of somatostatin-IR neurons in the human hypothalamus.	Somatostatin	120-132	tachykinin precursor 1	Homo sapiens	58-69
31574507-1	2020	The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly.	Somatostatin	23-35	somatostatin receptor 2	Rattus norvegicus	48-52
31574507-1	2020	The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly.	Somatostatin	23-35	gonadotropin releasing hormone receptor	Rattus norvegicus	57-71
31574507-1	2020	The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly.	Somatostatin	23-35	gonadotropin releasing hormone receptor	Rattus norvegicus	73-75
31904127-6	2019	Overall, the results obtained in the last two decades confirm that the initial pathologic mechanism of epileptogenic SCN1A/NaV 1.1 mutations is loss-of-function of NaV 1.1 leading to hypoexcitability of at least some types of gamma-aminobutyric acid (GABA)ergic neurons (including cortical and hippocampal parvalbumin-positive and somatostatin-positive ones).	Somatostatin	331-343	sodium voltage-gated channel alpha subunit 1	Homo sapiens	117-122
31904127-6	2019	Overall, the results obtained in the last two decades confirm that the initial pathologic mechanism of epileptogenic SCN1A/NaV 1.1 mutations is loss-of-function of NaV 1.1 leading to hypoexcitability of at least some types of gamma-aminobutyric acid (GABA)ergic neurons (including cortical and hippocampal parvalbumin-positive and somatostatin-positive ones).	Somatostatin	331-343	sodium voltage-gated channel alpha subunit 1	Homo sapiens	123-130
31904127-6	2019	Overall, the results obtained in the last two decades confirm that the initial pathologic mechanism of epileptogenic SCN1A/NaV 1.1 mutations is loss-of-function of NaV 1.1 leading to hypoexcitability of at least some types of gamma-aminobutyric acid (GABA)ergic neurons (including cortical and hippocampal parvalbumin-positive and somatostatin-positive ones).	Somatostatin	331-343	sodium voltage-gated channel alpha subunit 1	Homo sapiens	164-171
31731613-3	2019	Somatostatin analogues (SSAs) as monotherapy or in combination with growth hormone (GH)-receptor antagonists and/or dopamine agonists are used either alone or in combination following surgical failure to achieve disease control.	Somatostatin	0-12	growth hormone receptor	Homo sapiens	68-96
31798421-8	2019	Using the model, it is possible to reproduce the local disynaptic disinhibition of basket cells (fast GABAergic inhibition) and glutamatergic pyramidal neurons through long-range activation of vasoactive intestinal-peptide (VIP) interneurons that induced inhibition of somatostatin positive (SST) interneurons.	Somatostatin	269-281	vasoactive intestinal peptide	Homo sapiens	193-222
31798421-8	2019	Using the model, it is possible to reproduce the local disynaptic disinhibition of basket cells (fast GABAergic inhibition) and glutamatergic pyramidal neurons through long-range activation of vasoactive intestinal-peptide (VIP) interneurons that induced inhibition of somatostatin positive (SST) interneurons.	Somatostatin	269-281	vasoactive intestinal peptide	Homo sapiens	224-227
31719558-7	2019	Finally, calcium imaging revealed increased levels of neuronal activity in Grpr-Cre neurons upon application of somatostatin, which provides direct in vitro evidence for disinhibition of these dorsal horn interneurons.	Somatostatin	112-124	gastrin releasing peptide receptor	Homo sapiens	75-79
31844314-3	2020	Here we show in male mice that associative fear learning potentiates synaptic transmission and cue-specific activity of medial prefrontal cortex somatostatin (SST) interneurons and that activation of these cells controls both memory encoding and expression.	Somatostatin	145-157	somatostatin	Mus musculus	159-162
31835716-1	2019	Somatostatin released from the capsaicin-sensitive sensory nerves mediates analgesic and anti-inflammatory effects via the somatostatin sst4 receptor without endocrine actions.	Somatostatin	0-12	somatostatin receptor 4	Mus musculus	136-140
31765327-0	2019	Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma.	Somatostatin	0-12	proopiomelanocortin	Homo sapiens	69-73
31765327-3	2019	The biochemical sensitivity of the tumor to somatostatin analogues was tested by a 100 mug s.c. octreotide administration, which led to an ACTH and cortisol reduction of 50 and 25% respectively.	Somatostatin	44-56	proopiomelanocortin	Homo sapiens	139-143
31765327-5	2019	Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and -5).	Somatostatin	98-110	proopiomelanocortin	Homo sapiens	42-46
31765327-5	2019	Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and -5).	Somatostatin	98-110	somatostatin receptor 2	Homo sapiens	122-135
31631021-0	2019	Hippocampal CA1 Somatostatin Interneurons Originate in the Embryonic MGE/POA.	Somatostatin	16-28	carbonic anhydrase 1	Mus musculus	12-15
31631021-5	2019	We find a common origin for all hippocampal SST interneurons in NKX2-1-expressing progenitors of the telencephalic neuroepithelium and an MGE/POA-like transcriptomic signature for all SST clusters.	Somatostatin	44-47	NK2 homeobox 1	Mus musculus	64-70
31631021-6	2019	This suggests that functional heterogeneity within the SST CA1 population cannot be attributed to a differential MGE/CGE genetic origin.	Somatostatin	55-58	carbonic anhydrase 1	Mus musculus	59-62
31676823-3	2019	Here, we show that conditional loss of the Tuberous Sclerosis Complex (TSC) gene, Tsc1, which inhibits the mammalian target of rapamycin (MTOR), causes a subset of SST+ CINs, to express PV and adopt fast-spiking (FS) properties, characteristic of PV+ CINs.	Somatostatin	164-167	TSC complex subunit 1	Homo sapiens	71-74
31676823-3	2019	Here, we show that conditional loss of the Tuberous Sclerosis Complex (TSC) gene, Tsc1, which inhibits the mammalian target of rapamycin (MTOR), causes a subset of SST+ CINs, to express PV and adopt fast-spiking (FS) properties, characteristic of PV+ CINs.	Somatostatin	164-167	TSC complex subunit 1	Homo sapiens	82-86
31676823-3	2019	Here, we show that conditional loss of the Tuberous Sclerosis Complex (TSC) gene, Tsc1, which inhibits the mammalian target of rapamycin (MTOR), causes a subset of SST+ CINs, to express PV and adopt fast-spiking (FS) properties, characteristic of PV+ CINs.	Somatostatin	164-167	mechanistic target of rapamycin kinase	Homo sapiens	107-136
31676823-3	2019	Here, we show that conditional loss of the Tuberous Sclerosis Complex (TSC) gene, Tsc1, which inhibits the mammalian target of rapamycin (MTOR), causes a subset of SST+ CINs, to express PV and adopt fast-spiking (FS) properties, characteristic of PV+ CINs.	Somatostatin	164-167	mechanistic target of rapamycin kinase	Homo sapiens	138-142
31676823-7	2019	Moreover, they suggest that CINs can exhibit properties intermediate between those classically associated with PV+ or SST+ CINs, which may be dynamically regulated by the MTOR signaling.	Somatostatin	118-121	mechanistic target of rapamycin kinase	Homo sapiens	171-175
31597095-6	2019	In contrast, cells expressing somatostatin (CeA-Som) are inhibited by nerve injury and their activity drives antinociception.	Somatostatin	30-42	carcinoembryonic antigen gene family	Mus musculus	44-47
31636253-4	2019	Specifically, selective decreases are observed in interneurons that contain parvalbumin (PV) or somatostatin (SST).	Somatostatin	110-113	somatostatin	Homo sapiens	96-108
31636253-6	2019	We found that PV and SST had differential effects on neuronal activity and behavior when knocked down in the ventral hippocampus (vHipp) or medial prefrontal cortex (mPFC).	Somatostatin	21-24	complement factor properdin	Mus musculus	166-170
31725672-11	2019	CONCLUSION: The strategy involving continuous irrigation and suction with a triple-cavity drainage tube in combination with sequential somatostatin-somatotropin administration may be a safe and effective alternative treatment for postoperative high-output enterocutaneous fistula and a more practical method that is easy to execute to manage this problem.	Somatostatin	135-147	growth hormone 1	Homo sapiens	148-160
31566138-2	2019	Somatostatin (SST) is a natural peptide with growth inhibitory effect in several mammary cancer models.	Somatostatin	14-17	somatostatin	Homo sapiens	0-12
31551776-7	2019	Somatostatin release from sensory nerve endings of TRPA1 wild-type and knockout mice in response to polysulfide was detected by radioimmunoassay.	Somatostatin	0-12	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	51-56
31566138-7	2019	Distinct signaling pathways in these cell lines were studies: in MCF-7 cells, incubations with SST and Vit C, alone or in combination significantly decreased EGFR and MAPK signaling, whereas in MDA-MB231 cells, SST and Vit C incubations, alone or combined, decreased p-P44/42 MAPK levels, and increased EGFR levels.	Somatostatin	95-98	epidermal growth factor receptor	Homo sapiens	158-162
31566138-7	2019	Distinct signaling pathways in these cell lines were studies: in MCF-7 cells, incubations with SST and Vit C, alone or in combination significantly decreased EGFR and MAPK signaling, whereas in MDA-MB231 cells, SST and Vit C incubations, alone or combined, decreased p-P44/42 MAPK levels, and increased EGFR levels.	Somatostatin	95-98	epidermal growth factor receptor	Homo sapiens	303-307
31967012-2	2019	Medical management with somatostatin analogs and the growth hormone receptor antagonist pegvisomant can normalize insulin-like growth factor-1 (IGF1) levels after failed surgery and decrease mortality and comorbidities.	Somatostatin	24-36	insulin like growth factor 1	Homo sapiens	114-142
31967012-2	2019	Medical management with somatostatin analogs and the growth hormone receptor antagonist pegvisomant can normalize insulin-like growth factor-1 (IGF1) levels after failed surgery and decrease mortality and comorbidities.	Somatostatin	24-36	insulin like growth factor 1	Homo sapiens	144-148
32055175-6	2018	GLP-1R-immunoreactive cells were found in all types of pancreatic islets in both northern bobwhite and ostrich and expressed somatostatin immunoreactivity.	Somatostatin	125-137	glucagon like peptide 1 receptor	Gallus gallus	0-6
32055175-7	2018	The present results indicate that the pancreatic D cells are the target cells of GLP-1, and GLP-1 might play a physiological role via somatostatin in the avian species.	Somatostatin	134-146	glucagon	Gallus gallus	92-97